Literature DB >> 3498491

Purine deoxyribonucleosides counteract effects of hydroxyurea on deoxyribonucleoside triphosphate pools and DNA synthesis.

J Lagergren, P Reichard.   

Abstract

Inhibition of cell growth and DNA synthesis by hydroxyurea is thought to occur via an effect on the enzyme ribonucleotide reductase leading to a block of deoxyribonucleotide synthesis. Earlier attempts to bypass such a block by delivering deoxyribonucleosides to the medium of cultured cells have given equivocal results. Complications arise in such experiments from the specificity of the phosphorylating enzymes since 3 of the 4 deoxyribonucleosides are substrates for the same enzyme, with widely differing Km values, and from allosteric effects exerted by deoxyribonucleotides. We simplify this situation by using a mutant hamster V79 line that lacks the enzyme dCMP deaminase. The cells contain a 20-fold enlarged dCTP pool and require thymidine for optimal growth. Concentrations of hydroxyurea (50 or 100 microM) that in short-term experiments inhibited DNA synthesis depleted the dATP pool without seriously affecting pyrimidine deoxyribonucleotide pools. The dATP pool could be restored by addition of deoxyadenosine but this depleted the dGTP pool. This depletion could be counteracted by the simultaneous addition of deoxyguanosine but then critically depended on the relative concentrations of the two purine deoxyribonucleosides, with optimal results at 1 microM deoxyadenosine + 100 microM deoxyguanosine. Under those conditions the inhibition of DNA synthesis by hydroxyurea was partially reversed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498491     DOI: 10.1016/0006-2952(87)90213-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Buffering of deoxyribonucleotide pool homeostasis by threonine metabolism.

Authors:  John L Hartman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-02       Impact factor: 11.205

2.  Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase.

Authors:  Sarah E Huff; Faiz Ahmad Mohammed; Mu Yang; Prashansa Agrawal; John Pink; Michael E Harris; Chris G Dealwis; Rajesh Viswanathan
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

3.  Deoxyadenosine reverses hydroxyurea inhibition of vaccinia virus growth.

Authors:  M B Slabaugh; M L Howell; Y Wang; C K Mathews
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.

Authors:  B M Cantwell; D Veale; C Rivett; S Ghani; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  dNTP pools imbalance as a signal to initiate apoptosis.

Authors:  F J Oliver; M K Collins; A López-Rivas
Journal:  Experientia       Date:  1996-10-31

6.  5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.

Authors:  E E Vokes; J A Moormeier; M J Ratain; M J Egorin; D J Haraf; R Mick; R R Weichselbaum
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  A ribonucleotide reductase inhibitor with deoxyribonucleoside-reversible cytotoxicity.

Authors:  Mikael Crona; Paula Codó; Venkateswara Rao Jonna; Anders Hofer; Aristi P Fernandes; Fredrik Tholander
Journal:  Mol Oncol       Date:  2016-07-26       Impact factor: 6.603

8.  Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide.

Authors:  N S Kwon; D J Stuehr; C F Nathan
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

9.  In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.

Authors:  Nour N Al Zouabi; Mark L Xu; Z Ping Lin; Nicole E Bowen; Terence L Wu; Ethan S Lavi; Pamela H Huang; Yong-Lian Zhu; Baek Kim; Elena S Ratner
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.